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ABSTRACT
Purpose Changes in drug absorption and first-pass metabo-
lism have been reported throughout the pediatric age range.
Our aim is to characterize both intestinal and hepatic
CYP3A-mediated metabolism of midazolam in children in
order to predict first-pass and systemic metabolism of
CYP3A substrates.
Methods Pharmacokinetic (PK) data of midazolam and 1-OH-
midazolam from 264 post-operative children 1–18 years of age
after oral administration were analyzed using a physiological pop-
ulation PK modelling approach. In the model, consisting of phys-
iological compartments representing the gastro-intestinal tract and
liver,intrinsic intestinal and hepatic clearances were estimated to
derive values for bioavailability and plasma clearance.
Results The whole-organ intrinsic clearance in the gut wall
and liver were found to increase with body weight, with a 105
(95% confidence interval (CI): 5–405) times lower intrinsic gut
wall clearance than the intrinsic hepatic clearance (i.e. 5.08 L/
h (relative standard error (RSE) 10%) versus 527 L/h (RSE
7%) for a 16 kg individual, respectively). When expressed per
gram of organ, intrinsic clearance increases with increasing
body weight in the gut wall, but decreases in the liver, indicat-
ing that CYP3A-mediated intrinsic clearance and local bio-
availability in the gut wall and liver do not change with age in
parallel. The resulting total bioavailability was found to be
age-independent with a median of 20.8% in children
(95%CI: 3.8–50.0%).
Conclusion In conclusion, the intrinsic CYP3A-mediated gut
wall clearance is substantially lower than the intrinsic hepatic
CYP3A-mediated clearance in children from 1 to 18 years of
age, and contributes less to the overall first-pass metabolism
compared to adults.
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INTRODUCTION
Differences in drug absorption and first-pass metabolism have
been reported in children compared to adults (1–3). These
differences may for instance result from a smaller intestinal
surface area in children (2) and altered permeability across
age (1). In addition, besides gastric emptying time, intestinal
transit time, the production of bile fluid (3) and organ blood
flow to intestines and liver that may be altered in children (4),
intestinal and hepatic drug metabolizing enzyme activity may
be different from those in adults. For first-passmetabolism, the
activity of both intestinal and hepatic enzymes is of relevance,
while for systemic clearance the activity of hepatic enzymes is
important with activity of intestinal enzymes probably being
of negligible influence.
With cytochrome P450 (CYP) being an enzyme family in-
volved in metabolism of many drugs (5), this study focuses on
CYP3A enzymes, as they are abundant in both intestine and
liver (6,7). From the available in vitro and in vivo studies on the
ontogeny of CYP3A in children (8–10), there is some evidence
that the maturation and regulation of these enzymes in the gut
wall and liver may differ (11). However, the translation of en-
zyme activity in gut wall and liver to intestinal and hepatic
clearance is complex, because other parameters like organ
blood flow, organ size and other physiological parameters need
to be taken into account (4,12). In order to distinguish between
intestinal and hepatic clearance (and their maturation), a com-
bination of mechanistic and empirical models can be useful, as
was shown in adults before (13,14). This hybrid of approaches
seems necessary as for full physiologically-based PK models in
children not all parameters are always available and/or iden-
tifiable, while empirical models may lack direct physiological
interpretation. The latter is particularly problematic, because
both hepatic and intestinal metabolism contribute to first-pass
metabolism. As such, the combination of PBPK concepts with
population modelling using PK data from children enables
incorporation of prior knowledge of the system, while
obtainingmore insight into the system by parameter estimation
based on reverse translation of the observed clinical data (15).
In this study, the aim is to characterize both intestinal and
hepatic CYP3A-mediated metabolism of midazolam in chil-
dren between 1 and 18 years of age. We will adopt the above
described physiological population PK modelling approach,
in which we account for known changes in the physiology of
the gastrointestinal tract, and use the available PK data from
the population, to estimate the whole-organ intrinsic intestinal
and hepatic CYP3A-mediated midazolam clearance in chil-
dren. For this analysis, we had access to data from a clinical
study in which the CYP3A substrate midazolam which is
considered a probe drug for CYP3A (16), was administered
to children pre-operatively, and in which bothmidazolam and
the CYP3A-mediated metabolite (i.e. 1-OH-midazolam) con-
centrations were available.
METHODS
Data
In 873 plasma samples from 266 patients of the Children’s
Hospital of Philadelphia, PA, midazolam and 1-OH-
midazolam concentrations were measured (17). The children
received a median dose of 10 mg (range 3–15 mg) of midazo-
lam as oral suspension pre-operatively. Subjects include chil-
dren (150 boys/116 girls) between 1 and 18 years of age (me-
dian 7 years), with a median body weight of 27.2 kg (range
9.1–137.6 kg), who fit the criteria I or II of the American
Society of Anesthesiologist’s (ASA) classification, undergoing
surgery. In 31 patients, midazolam and its primary metabolite
were densely sampled around 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10
and 22 h after dose administration with a median of 10 sam-
ples per patient (range 8–11), and in 235 patients, samples
were sparsely collected for analysis at different time points
post-dose (median 2, range 1–3 samples/patient) with most
samples within the first four hours after dose administration
(figure S1). Data from two 14-year old patients in the sparsely
sampled group were excluded as their body weight was
<12 kg. The patient groups who were in the dense and sparse
sampled study were comparable in age and weight distribu-
tion (Table SI). Patient height and body surface area, required
for some of the covariate relationships in the model, were
derived from recorded age and body weight information
(equations in supplemental material).
Blood concentrations (B) were estimated based on the mea-
sured plasma concentrations (P) using eq. 1 (18):
B : P ¼ 1þ Hem  f u  K p−1
   ð1Þ
In whichHem is the hematocrit based on population values
reported in literature (19) ranging from 0.36 in 1- and 2-year-
old infants up to 0.41–0.43 in adolescents of 12–18 years of
age (Table I), the fu is the fraction unbound in plasma and Kp
is the unbound partition coefficient of the red blood cells to
plasma (assumed to be constant between adults and children)
(18). The fraction unbound in plasma for bothmidazolam and
1-OH-midazolam were calculated based on the formula of
McNamara and Alcorn (20):
f u;pediatric ¼
1
1þ
1− f u;adult
 
 P½ pediatric
P½ adult  f u;adult
ð2Þ
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where fu,pediatric and fu,adult are the fraction unbound of the
drug in plasma for children and adults respectively and
[P]pediatric and [P]adult are the plasma albumin concentrations
in children and adults respectively, assuming exclusive binding
to albumin for midazolam and its metabolite. The fractions
unbound of midazolam and 1-OH-midazolam in plasma in
adults were reported in literature (21,22). The albumin con-
centrations [P]pediatric are calculated based on the formula of
Johnson et al. (12):
P½ pediatric g=L½  ¼ 1:1287 ln Age yr½ ð Þ þ 33:746 ð3Þ
Measurements below the lower limit of quantification were
discarded according to the M6 method (23) (n= 4 (0.5%) and
n= 5 (0.6%) of midazolam and 1-OH-midazolam measure-
ments respectively).
Table I Parameter Values for System Specific and Drug Specific Parameters Included in the Physiological Population PK Model
Parameter name (unit) Parameter symbol Formula for calculation Value References
Tissue volumes (L)
Liver Vh 0.722× BSA
1.176 – (25)
Portal vein Vpv – 0.0052 (26)
Small intestine Vin 0.0467× age+ 0.0901 – (4)
Tissue blood flows (L/h)
Cardiac output CO BSA × (110+ 184.974 × (e-0.0378 × age - e-0.24477 × age)) – (27)
Hepatic blood flow Qh 0.28×CO (♀)
0.255×CO (♂)
– (27)
Portal vein
Hepatic artery
Qpv
Qha
0.75×Qh
0.25×Qh
– (12,52)
Small intestine
Mucosa
Microvilli
Qin
Qmuc
Qvilli
0.4×Qh
0.8×Qin
0.6×Qmuc
– (30,49)
Plasma proteins
Plasma albumin concentration (g/L) Ppediatric
Padult
1.1287× ln(age) + 33.746 -
37.7
(12)
Hematocrit (%) Hem1-2y
Hem3-6y
Hem7-12y
Hem12-18y,♀
Hem12-18y,♂
– 0.36
0.37
0.40
0.41
0.43
(19)
Midazolam
Fraction absorbed Fa – 1 (29)
Absorption rate constant (h−1) Ka – 4.16 –
Blood: plasma ratio B:P ratio 1= [Hem× (fu× Kp− 1)]with Kp=1 – (18)
Fraction unbound in gut Fu,G – 1 –
Fraction unbound in plasma Fu,plasma
Fu,adult
1
1þ
1− f u;adultð Þ P½ pediatric
P½ adult f u;adult
0.0303 (20)
(21)
Permeability through the enterocyte (L/h) CLperm CLperm = Peff,man × A with Peff,man = 4.4× 10
−4 cm/s – (30)
Intestinal surface area (dm2) A 2πr(r + h) with radius r =½× (0.016× BSA+ 0.0159)
and length h= 2.56× BSA+ 2.95
– (12)
1-OH-midazolam
Blood: plasma ratio B:P ratio B : P=1+ [Hem× (fu, M× Kp− 1)] with Kp=1 – (18)
Fraction unbound in plasma Fu,M,pediatric
Fu,M,adult
1
1þ
1− f u;M ;adultð Þ P½ pediatric
P½ adult f u;M ;adult
0.106 (20)
(22)
Age is expressed in years. A is the intestinal surface area in dm2 . BSA is the body surface area in m2 . Peff,man is the effective intestinal permeability per unit surface
area (dm/h). WT is body weight in kg
♀ female, ♂ male
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MODEL DEVELOPMENT
Structural Model
The physiological population PK analysis was performed
using NONMEM version 7.3 (ICON, Globomax LLC,
Ellicott, MD, USA) based on first-order conditional esti-
mation with interaction, and for visualization of data
Pirana 2.9.0, R (version 3.3.1), and R-studio (version
0.98.1078) were used. A physiological population phar-
macokinetic (PK) model, earlier developed and applied
by Yang et al. (24), Frechen et al. (13) and Brill et al. (14)
to describe midazolam PK data in adults, was now ap-
plied to describe the midazolam PK data in children 1–
18 years of age (Fig. 1). This model includes physiologi-
cal compartments representing the gut wall, the portal
vein and the liver, and also empirical central and periph-
eral compartments for midazolam and 1-OH-midazolam
distribution, representing the blood circulation and fast
equilibrating tissue, and peripheral slow equilibrating tis-
sues (13,24). Based on literature, central and peripheral
volumes were linearly scaled based on body weight from
a 76 kg healthy adult with volumes of 20.4 L/76 kg,
55.2 L/76 kg and 79.1 L/76 kg for the central and
two peripheral volumes for midazolam respectively and
with a volume of 65.7 L/76 kg for 1-OH-midazolam
(13). The fraction midazolam metabolized into 1-OH-
midazolam was assumed 100% (Table II).
In the physiological compartments, tissue volumes and
blood flows in children were based on literature data. The
hepatic volume (Vh) was calculated based on body surface
area (BSA, m2) (25):
Vh L½  ¼ 0:722 BSA1:176 ð4Þ
Volume of the portal vein was assumed to be equal to the
reported value of 5.2 mL in adults (26). To calculate the vol-
ume of the intestines, a regression line was derived from data
published by Björkman (4):
Vin L½  ¼ 0:0467 Age y½  þ 0:0901 ð5Þ
To calculate organ weight, the organ volumes are multi-
plied by the organ density of 1040 g/L (4). To compare with
adult values, organ weight in adults is calculated assuming
organ volumes of 1 L (13) and an organ density of 1040 g/L.
The hepatic blood flow (Qh) was assumed to be a fixed
percentage of the cardiac output (CO), which was calculated
based on BSA (27):
CO ¼ BSA  110þ 184:974 e0:0378 agee0:24477 age
  
ð6Þ
Fig. 1 Schematic representation of the physiological population PK model for midazolam and the metabolite 1-OH-midazolam. The extraction of midazolam is
defined by the well-stirred model in the liver and the ‘Qgut’ model in the gut wall. E = extraction ratio, F = bioavailability in the gut wall (gut, G) and the liver
(hepatic, H). CLint is the whole-organ intrinsic clearance in the gut wall and liver, Ka indicates the absorption rate constant and the fraction unbound in blood and
gut wall are described with fu,B and fu,G respectively. Blood flows are represented by Q; in the micro villi (Qvilli), portal vein (QPV), hepatic artery (QHA) and liver
(Qh). Distribution between central and peripheral (Periph.) compartments is estimated by inter-compartmental clearance Q1 and Q2 for the two peripheral
compartments for midazolam. Parameters describing the metabolite are indicated with the subscript M.
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Other tissue blood flows were assumed to be propor-
tional to the hepatic blood flow (Table I). The relation-
ship between plasma protein binding, intestinal surface
area, tissue volumes, and organ blood flows and body
weight for the individual patients in this study are
depicted in figure S2. For all physiological parameters in
Table I, population values were used without inter-
individual variability or uncertainty.
The absorption rate constant (ka) for midazolam could not
be estimated, and was therefore fixed at 4.16 h−1, yielding
peak concentrations to be reached round 30 min (tmax), which
is in agreement with the observed tmax and other reported
literature values (28). The oral bioavailability (Ftotal) was cal-
culated using:
Ftotal ¼ Fa  Fg  Fh ð7Þ
in which Fa is the fraction absorbed, which is assumed 1 for
midazolam (29), Fg is the gut wall bioavailability, equal to 1
minus the gut wall extraction ratio (Eg), and Fh is the hepatic
bioavailability, which is equal to 1 minus the hepatic extrac-
tion ratio (Eh). The hepatic extraction ratio of midazolam (EH)
and 1-OH-midazolam (EH,M) were defined by the well-stirred
model:
EH ¼
CLH ;int  f u;B
Q h þ CLH ;int  f u;B
  ð8Þ
where CLH,int is the estimated intrinsic hepatic clearance
(whole-organ), fu,B is the fraction unbound in the blood and
Qh is the hepatic blood flow. The gut wall extraction ratio is
described using the Qgut model (30):
EG ¼
CLG;int  f u;G
Q gut þ CLG;int  f u;G
  ð9Þ
Where CLG,int is the estimated intrinsic gut wall clearance
(whole-organ), fu,G is the fraction unbound in the gut, which
was assumed to be 1, andQgut is the effective blood flow at the
gut wall (30) which is defined by:
Q gut ¼
Q villi  CLperm
Q villi þ CLperm
ð10Þ
In which Qvilli is the villous blood flow and CLperm is the
permeability through the enterocytes of the gut wall for the
drug. This permeability factor depends on the effective
intestinal permeability per unit surface area (30) (Table I)
and the intestinal surface area A described by eq. 12, and
can be calculated using eq. 11.
CLperm ¼ Peff ;man  A ð11Þ
With A ¼ 2πr r þ hð Þ ð12Þ
where r is the intestinal radius in meters and h the intestinal
length inmeters, which are both calculated using a BSA-based
formula (eqs. 13 and 14) (12):
r ¼ §  0:016 BSA þ 0:0159ð Þ ð13Þ
h ¼ 2:56 BSA þ 2:95 ð14Þ
The total intestinal surface area was cut-off at a maximum
value of the adult value of 0.66 m2 (30) (figure S2). The total
plasma clearance was calculated using eq. 15:
CLplasma ¼ Qh CLH ;int  f u
Q h þ f u  CLH ;int
 
= B : P ratioð Þ ð15Þ
Where Qh is the hepatic blood flow, CLH,int is the
estimated intrinsic hepatic clearance, fu is the fraction
unbound in plasma, and B:P ratio is the blood-to-
plasma ratio of midazolam.
Statistical Model
Inter-individual variability in the estimated intrinsic clearance
parameters for midazolam and 1-OH-midazolam was includ-
ed in the model using the following equation:
CLint;i ¼ θTV  eηi ð16Þ
In which CLint,i is the individual intrinsic clearance esti-
mate for individual i, θTV is the typical value of the intrinsic
clearance in the studied population and ηi is a random vari-
able for the ith individual form a normal distribution with a
mean of zero and variance of ω2, yielding a log-normal distri-
bution for the parameter value in the population. Inter-
individual variability in the estimated intercompartmental
clearance parameters (Qcp1 and Qcp2) for midazolam was in-
cluded as well.
Residual unexplained variability was modelled using
a combined proportional and additive error model for
both midazolam and 1-OH-midazolam. The jth ob-
served concentration Y of the ith individual was
modelled according to:
Yij ¼ Cpred;ij  1þ ε1ij
 þ ε2ij ð17Þ
where Cpred,ij is the jth predicted midazolam concentra-
tion of the ith individual, ε1ij and ε2ij are random var-
iables from a normal distribution with a mean of zero
and variance of σ2.
Covariate Analysis
A covariate analysis for the estimated parameters (whole-
organ intrinsic clearance (CLG,int, CLH,int, CLH,int,M) and
Pharm Res (2018) 35: 182 Page 5 of 13 182
intercompartmental clearance (Qcp1, Qcp2)) was per-
formed in which the following covariates were tested for
significance: age, body weight, height, body surface area,
and sex. For sex, the typical value (θTV) for girls was
estimated relative to the value for boys. The remaining
continuous covariates were tested using a power (Eq. 18)
or linear (Eq.19) function.
Pi ¼ θTV  COVCOVmed
 	θCOV
ð18Þ
Pi ¼ θTV 

1þ θcov  COV−COV medð Þ ð19Þ
where Pi is individual parameter estimate for individual i, θTV
the typical value of the parameter in the studied population
with a median value (COVmed) of the covariate (COV) and
θCOV the estimated exponent or slope for a power or linear
function respectively.
Model Evaluation
Structural models were evaluated by comparison of the objec-
tive function values (OFV, i.e. -2 × log-likelihood). A decrease
of 3.84 in the OFV between nested models (p < 0.05) was
considered statistically significant. In addition, goodness-of-
fit plots of midazolam and 1-OH-midazolam were assessed,
in which observed versus individual- and population-predicted
concentrations and conditional weighted residuals (CWRES)
versus time and population predicted concentrations are visu-
alized. Moreover, the condition number, the confidence inter-
val of the parameter estimates, and visual improvement of the
individual plots were used to evaluate the models.
For inclusion of covariates, a drop in OFV by at least 6.64
points (p< 0.01) was considered statistically significant, while
for the backward deletion a more stringent p value (p< 0.005,
ΔOFV>7.88) was used. Moreover, to retain a covariate in the
model, the inter-individual variability in the PK parameter
should decrease.
Two methods were applied to evaluate the final model
internally. A bootstrap analysis (n= 250) was performed to
evaluate model stability and parameter precision (31). In ad-
dition, a normalized prediction distribution error (NPDE)
analysis was performed using the NPDE package in R (32).
For each observed concentration, 1000 midazolam concen-
trations were simulated based on the parameter values that
were obtained for the original model (Table II). The observed
concentrations were compared to the range of 1000 predicted
concentrations. The Wilcoxon signed rank test was used to
assess the deviation of the observed mean value of the
NPDE to the expected value of 0, and the Fisher variance test
was used to assess the deviation of the observed variance from
the expected value of 1.
Sensitivity Analysis
A sensitivity analysis was performed to evaluate the assump-
tions made in the model. For this, it was evaluated what the
impact was of a 50% increase or decrease of the parameter
values for intestinal length, the fraction unbound and tissue
volumes and blood flows on predicted midazolam concentra-
tions and on the estimated model parameters. Additionally,
the impact of the assumed fraction absorbed (Fa) of 1 (29), on
the estimated whole-organ intrinsic clearance in the gut wall
and liver, and the derived total plasma clearance, was evalu-
ated, as well as a 50% increase or decrease of volume of
distribution of the primary metabolite, 1-OH-midazolam.
RESULTS
In themodel as shown in Fig. 1, the intrinsic gut wall clearance
was 5.08 L/h (with a relative standard error (RSE) of 16%)
and the intrinsic hepatic clearance was 527 L/h (RSE 7%) for
a typical individual of 16 kg (Table II). The increase in these
whole-organ intrinsic clearance values, reflected by the inclu-
sion of a power function (eq. 18) correlating body weight as
covariate to intrinsic clearance with an exponent of 0.807
(RSE 10%) and 0.472 (RSE 16%) for intestinal and hepatic
maturation respectively, appeared to be slightly larger in the
gut wall than in the liver (Table II). For intercompartmental
clearance of midazolam to the first peripheral compartment
(with Vp1 = 55.2 L), body weight was found as a covariate,
while no covariate was identified for intercompartmental
clearance to the second peripheral compartment (with
Vp2 = 79.1 L). Lastly, a covariate was included in the model
correlating weight to intrinsic hepatic clearance of the metab-
olite with an exponent of 0.651 (RSE 9%). Age, height, body
surface area, and sex were not identified as covariates for the
estimated parameters. The gut wall metabolism of the metab-
olite could not be estimated independently due to model in-
stability, and was therefore estimated as a fraction of the gut
wall metabolism of midazolam. The bootstrap results con-
firmed the model stability and the precision of parameter es-
timates of the model (Table II).
Figure 2a illustrates the relation between body weight and
whole-organ intrinsic clearance in the gut wall and the liver.
As illustrated in this figure, the intrinsic hepatic clearance was
estimated to be around 105 times higher than the intrinsic gut
wall clearance for a typical individual of 16 kg, while this
factor differed largely between individuals (factor of 5–405,
95%CI). When the gut wall and hepatic intrinsic clearances
are expressed per gram of organ, an inverse trend can be
observed for hepatic intrinsic CYP3A activity per gram of
organ. In Fig. 2b, the intrinsic clearance per gram of organ
are plotted versus age, which shows a (slight) decrease in hepatic
intrinsic CYP3A activity per gram of liver with age, while no
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change with age is observed for gut wall intrinsic CYP3A
activity per gram of small intestine except for a small drop
around the age of 4–5 years.
Using eq. 15, the total plasma clearance was derived and
plotted against body weight, showing that total plasma clear-
ance also increases with body weight (Fig. 3). For comparison,
in Fig. 2a, b and 3, literature values on whole-organ intrinsic
and total plasma clearance in adults have been added (13).
Using the estimated whole-organ intrinsic clearance values,
together with blood flow and fraction unbound, the extraction
ratios Eg and Eh (eqs. 8 and 9) and bioavailability values Fg
and Fh (i.e. 1-Eg or Eh, respectively) were derived. Figure 4
shows the results with gut wall bioavailability first slightly in-
creasing and then decreasing with age, while the hepatic bio-
availability showed an overall increase with age. More specif-
ically, the hepatic bioavailability is increasing with body
weight from a median of 58% (range 35–79%) to 73% (range
58–86%) from 1 to 2 year old to children 12–18 years of age
(p< 0.001, Wilcoxon-Mann-Whitney U-test) (Fig. 4). With re-
spect to the gut wall bioavailability, the median of 37% (range
8–85%) in 1–2 year old children increases to 39% (range 6–
82%) in children of 3–5 years of age, then to decrease to 34%
Table II Parameter Estimates of the Final Physiological Population PK Model
Parameter definition Parameter (unit) Value (RSE%)
[shrinkage %]
Bootstrap
median
Bootstrap 90% CI 70-kg
individual
Midazolam
Intrinsic hepatic clearance CLH,int,i = CLH,int,16kg × (WT/16)
k1 CLH,int,16kg (L/h) 527.0 (7%) 601.4 523.5–748.6 1057
Exponent k1 0.472 (16%) 0.425 0.206–0.554 0.472
Intrinsic gut wall clearance CLG,int,i = CLG,int,16kg × (WT/16)
k2 CLG,int,16kg (L/h) 5.08 (10%) 4.93 3.32–6.17 16.7
Exponent k2 0.807 (10%) 0.881 0.622–1.27 0.807
Volume of distribution (central) Vc,i = Vc,76kg × (WT/76)
k3 Vc,76kg (L) 20.4 fix – – 18.8
Volume of distribution (two peripheral compartments)
Vp,i = Vp,76kg × (WT/76)
k3
Vp1,76kg (L)
V p2,76kg (L)
55.2 fix
79.1 fix
-
-
– 50.8
72.9
Exponent k3 1 fix – – 1
Inter compartmental clearance Qcp1,i = Vcp1,16kg × (WT/16)
k4 Qcp1 (L/h) 14.9 (19%) 14.9 8.9–25.9 57.9
Exponent k4 0.92 (21%) 1.03 0.796–1.65 0.92
Inter compartmental clearance (2nd peripheral compartment) Qcp2 (L/h) 7.5 (10%) 7.7 6.3–11.2 7.5
1-OH-midazolam (M)
Fraction midazolam metabolized into 1-OH-midazolam fM 1 fix – – 1
Intrinsic hepatic clearance CLH,int,M,i = CLH,int,M,16kg × (WT/16)
k5 CLH,int,M,16kg (L/h) 235.0 (6%) 236.2 219.6–269.6 614.2
Exponent k5 0.651 (9%) 0.615 0.451–0.750 0.651
Intrinsic gut wall clearance
CLG,int,M,i = k6×CLG,int,i
k6 18.4 (12%) 19.2 10.6–198.2 18.4
Volume of distribution
VM,i = VM,76kg × (WT/76)
k7
VM,76kg (L) 65.7 fix – – 60.5
Exponent k7 1 fix – – 1
Inter individual variability (variance)
Intrinsic hepatic clearance ω2 CLH,int 0.25 (13%)[25%] 0.24 0.16–0.32 –
Intrinsic gut wall clearance ω2 CLG,int 1.20 (13%)[13%] 1.25 1.04–1.56 –
Inter compartmental clearance ω2 Qcp1 1.05 (35%)[42%] 1.05 0.26–1.85 –
ω2 Qcp2 1.06 (31%)[46%] 1.06 0.68–1.79 –
Intrinsic hepatic clearance 1-OH-midazolam (M) ω2 CLH,int,M 0.13 (18%)[31%] 0.13 0.08–0.19 –
Residual variability (variance)
Proportional error (Midazolam) 0.166 (8%)[19%] 0.169 0.150–0.199 –
Additive error (Midazolam), nmol/L 0.001 fix – – –
Proportional error (1-OH-midazolam) 0.292 (11%)[9%] 0.271 0.225–0.309 –
Additive error (1-OH-midazolam), nmol/L 0.528 (10%)[9%] 0.454 0.130–0.826 –
RSE: relative standard error. CI: the 5th–95th percentiles are shown, indicating a 90% confidence interval. Bootstrap n=250. Inter-individual and residual
variability values are shown as variance estimates. Intrinsic clearance values are reported for the whole organ
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(range 3–84%) and 29% (range 4–66%) in children of 6–12
and 12–18 years of age, respectively. With total bioavailability
being equal to Fg times Fh (eq. 7), Fig. 4 shows that no or only
small changes in the total bioavailability for children up to
12 years of age can be expected. In adolescents, the gut wall,
hepatic and total bioavailability proved not significantly dif-
ferent from the values observed in adults which were obtained
from literature (p> 0.05).
Figure S3 shows the goodness-of-fit plots of both midazo-
lam and its primary metabolite. These plots for midazolam
indicated no bias for midazolam in the individual and popu-
lation concentration predictions versus the observed concentra-
tions (figure S3 A,B) and no trend or bias in the conditionally
weighted residuals versus the predicted concentrations or time
after dose (figure S3 C,D). Also the presystemic formation of
1-OH-midazolam was well described by the model, as except
for a small under prediction of the peak concentrations (figure
S3 E), no bias in the goodness-of-fit plots for the metabolite
was observed (figure S3 E-H). The normalized prediction dis-
tribution error (NPDE) results showed no bias in the concen-
tration predictions for bothmidazolam and 1-OH-midazolam
(figure S4), indicating no structural model misspecification.
The variance of midazolam concentrations however was
under-estimated in our model (Fisher variance test, p <
0.001), while the model adequately captures the variability
for 1-OH-midazolam concentrations.
The sensitivity analysis (table SII) showed that changing
volumes of the gut wall or liver by 50% does not considerably
impact the predicted concentrations (<10%) nor our param-
eter estimates for whole-organ intrinsic clearance for gut wall
and liver. With a 50% increase or decrease in hepatic blood
flow, the whole-organ intrinsic hepatic clearance inversely
changes with −14% and + 49% respectively. A similar trend
was found for intestinal blood flow and intestinal length (table
SII). A change in fraction unbound in blood resulted in a
change in whole-organ intrinsic hepatic clearance by the same
factor. If the fraction midazolam that gets absorbed (Fa) is
smaller than 100%, the median total bioavailability does not
change considerably. While the hepatic bioavailability is not
impacted, the gut wall bioavailability however increases by 4.1
and 18.7% for an Fa of 0.90 and 0.80, respectively. A change
in the volume of distribution of the primary metabolite leads
to considerable changes in all clearance parameters. All results
of the sensitivity analysis are summarized in the supplemental
material (table SII).
Fig. 2 First-pass metabolism parameters in children. (a) Intrinsic whole-
organ intestinal (■) and hepatic (○) clearance versus body weight, both indi-
vidually predicted (symbols) and the population predictions (lines) for children
in our study. Also illustrated are the reported literature values of 26.7 and
1640 L/h for intestin al ( ) and hepatic ( ) clearance in adults, respectively
(13). (b) Intrinsic gut wall (■) and hepatic (○) clearance per gram of organ
versus age for children in our study and for adults(–), both individually predict-
ed (symbols) and a loess curve of the population predictions (lines) for children
in our study.
Fig. 3 Total hepatic plasma clearance versus body weight for children in our
study (○) and calculated plasma clearance in adults ( ) based on the reported
typical hepatic whole-organ intrinsic clearance of 1640 L/h, a hepatic blood
flow increasing with body weight (Qh= 3.75∙WT
0.75), a fraction unbound of
0.0303 and a blood: plasma ratio of 0.66 (13) using eq. 15.
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DISCUSSION
To characterize both intestinal and hepatic CYP3A-mediated
metabolism of midazolam in children between 1 and 18 years
of age, a physiological population PK model was developed
(Fig. 1). The physiological population PKmodelling approach
we applied has been previously applied in healthy adults (13)
and morbidly obese versus bariatric surgery patients (14), and
this approach has now proven useful in distinguishing between
metabolism by intestinal and hepatic CYP3A enzymes in chil-
dren as well.
Using PK data from one of the few clinical studies in which
children varying in age between 1 and 18 years old received
midazolam orally (17), we showed that the whole-organ in-
trinsic clearance of gut wall and liver do not change in parallel
(Fig. 2a). For all pediatric ages, the intrinsic hepatic clearance
is higher than the intrinsic gut wall clearance, while the gut
wall clearance appears to increase slightly faster than hepatic
clearance (Fig. 2a). The estimated clearance values for the
patients with the highest body weight (>16 years of age) are
with 16.1 L/h and 1051 L/h in the same order of magnitude
as the reported values of 26.7 L/h and 1640 L/h for intrinsic
intestinal and hepatic clearance in adults respectively (13). As
we used the whole-organ intrinsic clearance of midazolam as
surrogate marker of total hepatic and intestinal CYP3A activ-
ity in this study, we found that the total intestinal CYP3A
activity is lower than the hepatic CYP3A activity. However,
when expressed per gram of organ, no increase in intrinsic gut
wall clearance per gram of organ can be observed, while the
intrinsic hepatic clearance per gram of liver is highest in the
youngest children and decreases with age (Fig. 2b).
The increase in whole-organ intrinsic clearance in the gut
wall we report here can be mostly attributed to the organ
growth and the increasing total weight of the enterocytes in
children (33,34), as per gram of gut wall no trend with increas-
ing age (Fig. 2b) or body weight can be observed in children
>2 year of age. The intrinsic intestinal CYP3A4 expression
per gram of small intestine in children has been described to
be slightly higher in children <2 years of age, compared to 2–
5 year old children, and then increases with age (33). This is in
agreement with the small drop in gut wall intrinsic CYP3A
activity per gram of small intestine we observe around the age
of 4–5 years (Fig. 2b), and in combination with the other
physiological changes this leads to a higher gut wall bioavail-
ability in children 3–5 year of age compared to children 1–
2 years of age, and a decrease in gut wall bioavailability with
increasing age in children >3 years of age, which is in agree-
ment with the trend observed in Fig. 4.
We report the whole-liver intrinsic hepatic CYP3A-
mediatedmetabolism to increase with increasing body weight,
which can be attributed to an increasing total liver weight (4).
In literature, the amount of microsomal protein in the liver is
believed to remain constant with age (35), while the CYP3A4
abundance per gram of microsomal protein (8,36) has been
reported to increase with age. Our results however show a
slight decrease in intrinsic clearance per gram of liver through-
out the pediatric age range, suggesting that the absolute abun-
dance or activity of CYP3A4 per gram of liver slightly de-
creases with age in children 1–18 years of age.
The extraction ratios Eg and Eh can be derived from the
estimated whole-organ intrinsic clearance, the organ blood
flows and the fraction unbound (Eqs. 8 and 9), and can be
subsequently used to calculate the bioavailability (i.e. Fg and
Fh). The fraction escaping gut wall metabolism was found to
be smaller (median Fg 0.34, range 0.02–0.85) than the fraction
escaping hepatic metabolism (median Fh 0.66, range 0.35–
0.93). These values for hepatic bioavailability are in agree-
ment with previously reported values in adults (13,37). The
median hepatic bioavailability increases with body weight due
to a smaller increase in whole-organ intrinsic hepatic clear-
ance relative to the hepatic blood flow (Fig. 4), while an in-
verse, but smaller age-related trend in median intestinal bio-
availability was found as the effective blood flow in the gut
wall (Qgut) increases less with age than the whole-organ intrin-
sic intestinal clearance.
In adults, the local bioavailability in the gut wall is much
lower than in the liver with reported values for Fg and Fh
around 0.2 and 0.7, respectively (13), and therefore in adults
the extraction ratio in the gut wall is higher than in the liver,
indicating that intestinal CYP3A enzymes play a large role in
presystemic metabolism despite the low whole-organ intrinsic
clearance. In children, the intrinsic gut wall CYP3A activity is
lower than in adults (Fig. 2a), and together with a lower effec-
tive blood flow, this leads to a higher gut wall bioavailability
compared to adults (Fig. 4). This indicates that the role of gut
wall metabolism in presystemic metabolism is smaller in chil-
dren compared to adults, and also gets smaller with decreasing
age. This is compensated by the increased whole-organ intrin-
sic hepatic CYP3A-mediated intrinsic clearance (Fig. 2a),
which together with the hepatic blood flow leads to lower
hepatic bioavailability with decreasing age (Fig. 4), resulting
in an age-independent total bioavailability Ftotal with a medi-
an value of 20.8% (Fig. 4).
The parameters for clearance and total bioavailability are
in agreement with literature. For clearance, the plasma clear-
ance can be calculated based on the estimated intrinsic hepatic
clearance, the fraction unbound, the hepatic blood flow and
the blood-to-plasma ratio (eq. 15). The derived total plasma
clearance of 6.0 L/h in the youngest children of 1–2 years of
age to 17.5 L/h in the older children ≥16 years of age (Fig. 3),
is in agreement with literature values of 0.6 L/h/kg (0.56–
0.68 L/h/kg) (28). For patients in the age range between
2 months and 3 years, median clearance values around 9 L/
h have been reported in patients after major craniofacial sur-
gery (38) and in patients with severe malaria (39), which is
in agreement with our findings. Furthermore, it has been
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reported that disease severity impacts CYP3A-mediated
clearance (40), and as the children in this study are rela-
tively healthy (ASA criterion I or II), clearance is indeed a
factor 2–4 higher than the reported midazolam clearance
in critically ill children (40–43).
For bioavailability, the median total bioavailability of
20.8% (mean 22.7 ± 12.4%) across the pediatric age range is
similar to the reported median value of 13.4% (13) or the
reported mean ± SD of 34.3%± 10% (37) in adults, but the
observed variability in total bioavailability in the children in
our study was very large, with values ranging from 1.5–77.9%
A previous study in pediatric patients ranging in age from
6 months to 16 years, who had ASA physical status I-III,
found similar values for bioavailability (28) and also found a
large variability with the bioavailability ranging from 9 to
71% (28). This high variability has also been described in
other studies (44,45), and may be explained by the high unex-
plained variability in intestinal CYP3A activity, which may be
due to e.g. the circadian rhythm (46), the (genetic) variability
in CYP3A5 expression (47), and the different regulation of the
gut (11) as a result of exposure to variable food and other
environmental effects in different individuals throughout their
life (48). This implicates that oral administration will result in
highly variable PK profiles and exposure of CYP3A substrates
in children, which is relevant in the clinic setting as well as
during drug development.
All parameters in the model could be estimated with good
precision (RSE < 30%, Table II) and the model stability was
evaluated by bootstrap (Table II), which confirmed the preci-
sion of the parameter estimates. Furthermore, the goodness-
of-fit plots showed that the concentrations of both midazolam
and 1-OH-midazolam were well-predicted without bias
(figure S3), indicating accurate model predictions for both
the parent compound and the metabolite. Figure S4 shows
the normalized prediction distribution errors versus predicted
concentrations and versus time after first dose, which demon-
strates accurate prediction of the midazolam and 1-OH-
midazolam concentrations and variability, with only a small
over-prediction of the variability of midazolam.
The model is based on accepted PBPK principles, and
well-known equations and parameter values from the litera-
ture have been used. For unknown parameter values in the
pediatric population, assumptions and scaling methods were
applied and a sensitivity analysis was performed for these pa-
rameters (Table SII). For hepatic blood flow, the flow was
assumed to be a fixed percentage of the cardiac output
(25.5% in boys and 28% in girls) (27), which results in blood
flow values in agreement with other literature values (49,50).
The sensitivity analysis indicated that if the hepatic or the
intestinal blood flow would be 50% higher or lower, that peak
concentrations would be impacted, but the derived values for
extraction ratio and bioavailability were not impacted by this
assumption. Moreover, actual blood flows will likely deviate
less than 50% from the assumed flows. The assumed tissue
volumes (figure S2 C) are in agreement with other literature
values (51), and the sensitivity analysis indicated no impact of
these assumptions on the results regarding the predicted plas-
ma concentrations and the derived values for extraction ratio
and bioavailability. Plasma protein binding to albumin has
been accounted for in the model (eq. 2), while no protein
binding to other plasma proteins was assumed, and the range
of fraction bound was with 96.1–96.4% in agreement with the
97.0% protein binding reported in adults (figure S2 A).
Furthermore, our sensitivity analysis indicated that assuming
50% increase or decrease in intestinal length, would lead to
+9.3 or − 37.2% change in whole-organ intrinsic gut wall
Fig. 4 Bioavailability in in the gut wall (Fg), in the liver (Fh) and total bioavailability (Ftotal) for four different age categories: children of 1–2 years, 3–5 years, 6–
11 years, and 12–18 years of age (increasing dark grey) compared to adult values (13). A nonparametric test of group differences was performed using the
independent 2-group Wilcoxon-Mann-Whitney Test, with *** indicating a p-value <0.001, ** for p<0.01, * for p<0.05 and ‘NS’ for p>0.05. Adult
bioavailability values are calculated based on their reported typical whole-organ intrinsic hepatic clearance, hepatic blood flow for their body weight and the
fraction unbound (see eqs. 8 and 9) (13).
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clearance respectively, without affecting the estimated extrac-
tion ratio and bioavailability. This is because the intestinal
length impacts the permeability factor of the gut wall and
thereby the effective blood flow in the gut wall. Since the
amount of drug reaching the systemic circulation is derived
from the PK data and does not change, an increase in intes-
tinal length is compensated by a decrease in whole-organ in-
trinsic gut wall clearance so that the extraction ratio and bio-
availability remain constant.
The absorption rate constant could not be estimated in our
model, as sampling at early time points was limited and there-
fore we included an absorption rate constant of 4.16 h−1,
which means that maximum concentrations are reached
around 30 min post-dose, which was close to the median ob-
served Tmax and reported values in literature (28). As in this
study only oral midazolam was administered, we could not
estimate the volume of distribution for midazolam and its
metabolite. We therefore linearly scaled the volumes of the
central and peripheral compartments from a 76 kg healthy
adult (13) to children. The sensitivity analysis showed that
the volume of distribution of the metabolite is impacting all
estimated clearance parameters considerably (Table SII), but
the assumed distribution volumes are in agreement with pre-
viously reported values for volume of distribution in children
(28,39). Moreover, since we could not estimate inter-
individual variability (IIV) in volume of distribution, all
inter-individual variability is in the model attributed to the
intrinsic clearance parameters and the residual variability,
both of which may therefore be inflated.
Furthermore, we assumed that all midazolam is metabo-
lized by CYP3A into its primary metabolite, 1-OH-midazo-
lam, and the volume and clearance values of the metabolite
should therefore be considered as apparent values assuming a
100% formation. As these assumptions on volume of distribu-
tion and fraction metabolized are supported by literature
(28,39), the PK data of both midazolam and 1-OH-
midazolam are well-described (figure S3, S4), and the intrinsic
clearance values lead to total plasma clearance and bioavail-
ability in range with previous published work (28,38,39), the
intestinal and hepatic intrinsic clearance values are indeed
well-estimated by the model and could therefore be used as
surrogate marker for gut wall and hepatic CYP3A activity in
children. As hepatic CYP3A4 is the most abundance cyto-
chrome P450 enzyme and responsible for metabolism of a
wide variety of therapeutics, the observed midazolam clear-
ance as probe for CYP3A activity may have implications for
other CYP3A substrates as well. It is also clinically relevant for
patients receiving multiple CYP3A substrates or inhibitors/
enhancers as different drug-drug interactions in children versus
adults may be anticipated. However, as the variability in oral
bioavailability is very high, a highly variable drug exposure
may be anticipated when CYP3A substrates are orally
administered.
To conclude, this is the first study in children 1–18 years of
age to distinguish between pediatric intestinal and hepatic
CYP3A-mediated metabolism using clinical data together
with PBPK principles. The results show that the whole-
organ intrinsic hepatic clearance appears much higher than
the gut wall clearance, but also that the difference between the
whole-organ intrinsic clearances in children is smaller com-
pared to adults. As a result, the intrinsic CYP3A-mediated
gut wall clearance in children from 1 to 18 years of age con-
tributes less to the overall first-pass metabolism compared to
adults. Organ growth is the most important contributing fac-
tor to the increase in the whole-organ intrinsic CYP3A clear-
ance in gut wall and liver with age, given the fact that the
intestinal CYP3A activity per gram of organ remained rela-
tively constant throughout childhood and the hepatic CYP3A
activity per gram of liver even decreased slightly. While intes-
tinal bioavailability decreased with age, the hepatic bioavail-
ability increased with age, resulting in no change in total bio-
availability in children with increasing age and body weight.
This indicates an age-independent but highly variable first-
pass effect by intestinal and hepatic CYP3A enzymes in chil-
dren from 1 to 18 years of age.
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